Author details

Full Name

Manuel Comabella

Affiliation

ORCID

Career Start Year

1993

Papers

289

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37754568	Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients.	Eur J Neurol	2024
36848127	Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.		2023
36344261	Increased cytomegalovirus immune responses at disease onset are protective in the long-term prognosis of patients with multiple sclerosis.	Journal of Neurology, Neurosurgery and Psychiatry	2023
36427295	Associations of sNfL with clinico-radiological measures in a large MS population.	Ann Clin Transl Neurol	2023
36411079	Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.	Neurology: Neuroimmunology and NeuroInflammation	2023
37940409	Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.		2023
37841253	Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: antiviral activity and clinical response.		2023
37728389	A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.		2023
37803817	Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI.		2023
37705507	Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis.		2023
37559720	Molecular signature associated with cladribine treatment in patients with multiple sclerosis.		2023
37702323	Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury.	Clin Chem Lab Med	2023
36973075	Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure.		2023
37468284	Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.		2023
36940621	Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI.		2023
37183562	The CYP24A1 gene variant rs2762943 is associated with low serum 1,25-dihydroxyvitamin D levels in multiple sclerosis patients.		2023
36534392	Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.		2023
37508574	Liquid Biopsy in Neurological Diseases.		2023
35088080	Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis.	Human Molecular Genetics	2022
35487685	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis.	Journal of Neurology, Neurosurgery and Psychiatry	2022
35727945	The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria.	Brain	2022
35476319	Multiple sclerosis: Immunopathological heterogeneity and its implications.	European Journal of Immunology	2022
35538884	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-cell-autonomous neuronal damage.	Clinical and Translational Medicine	2022
35475363	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?	Multiple Sclerosis Journal	2022
36403026	Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.	Journal of Neuroinflammation	2022
33870790	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.	Multiple Sclerosis Journal	2022
34800172	Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.	Journal of Neurology	2022
35192034	Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.	Journal of Neurology	2022
34841948	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.	Multiple Sclerosis Journal	2022
34596743	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.	Journal of Neurology	2022
35111166	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the <i>ANKRD55</i>-<i>IL6ST</i> Gene Region in Immature Dendritic Cells.	Front Immunol	2022
35001198	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.	Journal of Neurology	2022
35105687	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.	Neurology: Neuroimmunology and NeuroInflammation	2022
34691084	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab.	Frontiers in Immunology	2021
34234733	Angiogenin in the Neurogenic Subventricular Zone After Stroke.	Frontiers in Neurology	2021
33903203	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.	Neurology: Neuroimmunology and NeuroInflammation	2021
34219266	Targeting Inflammasomes to Treat Neurological Diseases.	Annals of Neurology	2021
33565909	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.	Multiple Sclerosis Journal	2021
34322119	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis.	Frontiers in Immunology	2021
33293459	Chitinases and chitinase-like proteins as biomarkers in neurologic disorders.	Neurology: Neuroimmunology and NeuroInflammation	2021
33340215	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.	European Journal of Neurology	2021
33328323	Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials.	Neurology	2021
33327838	Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.	Multiple Sclerosis Journal	2021
34521693	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.	Neurology	2021
34725369	Genetic variation in NDFIP1 modifies the metabolic patterns in immune cells of multiple sclerosis patients.	Scientific Reports	2021
34385365	Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis.	Neurology: Neuroimmunology and NeuroInflammation	2021
34497102	CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis.	Neurology: Neuroimmunology and NeuroInflammation	2021
34943995	Immunomodulatory Effects Associated with Cladribine Treatment.	Cells	2021
31368393	The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States.	Mult Scler	2020
32431704	A Polymorphism Within the Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis.	Frontiers in Immunology	2020